At a glance
ClinicalIndex Comparison RecordN/ACompleted· 27 enrolled
Drug / intervention
Gardasilbiological
Likely dose
Gardasil 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety of the Quadrivalent HPV Vaccine Gardasil in Female Systemic Lupus Erythematosus Patients Aged 9-26
In Brief
A clinical study evaluating Gardasil for Systemic Lupus Erythematosus. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the immunogenicity and safety of the HPV vaccine Gardasil in young women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionAug 2010
Study CompletionDec 2011
TodayJul 2026
First PostedNov 6, 2008
Enrollment StartNov 1, 2008
Primary CompletionAug 1, 2010
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.7 years ago
Interventions
Gardasilbiological
0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.